Axicabtagene-ciloleucel/lisocabtagene-maraleucel/tisagenlecleucelVarious toxicities

被引：0

作者：

机构：

来源：

Reactions Weekly | 2024年 / 1999卷 / 1期

关键词：

D O I：

10.1007/s40278-024-54375-1

中图分类号：

学科分类号：

摘要：

引用

页码：66 / 66

共 50 条

[21] Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis
Meng, Jun
Wu, XiaoQin
Sun, Zhen
Xun, RenDe
Liu, MengSi
Hu, Rui
Huang, JianChao
FRONTIERS IN ONCOLOGY, 2021, 11
[22] Axicabtagene-ciloleucel/dexamethasoneCytokine release syndrome, myelodysplastic syndrome and lack of efficacy: case report
Reactions Weekly, 2023, 1976 (1) : 65 - 65
[23] Axicabtagene ciloleucel/fluconazole/tocilizumabVarious toxicities: 4 case reports
Reactions Weekly, 2023, 1976 (1) : 64 - 64
[24] Axicabtagene-ciloleucel/brexucabtagene-autoleucel/tisagenlecleucelCytokine release syndrome and cardiotoxicites: 3 case reports
Reactions Weekly, 2022, 1892 (1) : 52 - 52
[25] Idecabtagene-vicleucel/lisocabtagene-maraleucel/tocilizumabCytokine release syndrome, atrial fibrillation and lack of efficacy: 2 case reports
Reactions Weekly, 2023, 1964 (1) : 222 - 222
[26] COST-EFFECTIVENESS ANALYSIS OF AXICABTAGENE CILOLEUCEL, LISOCABTAGENE MARALEUCEL, AND TISAGENLECLEUCEL CAR T-CELL THERAPIES FOR TREATMENT OF RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (LBCL)
Ghanem, B.
Seoane-Vazquez, E.
Fleming, M.
Brown, L. M.
Rodriguez-Monguio, R.
VALUE IN HEALTH, 2023, 26 (06) : S75 - S75
[27] Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US
Oluwole, Olalekan O.
Liu, Rongzhe
Diakite, Ibrahim
Feng, Chaoling
Patel, Anik
Nourhussein, Iman
Snider, Julia Thornton
Locke, Frederick L.
JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 541 - 551
[28] Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States
Parker, Christopher
Liu, Fei Fei
Deger, Kristen A. A.
Franco-Villalobos, Conrado
Proskorovsky, Irina
Keating, Scott J. J.
Sorensen, Sonja
ADVANCES IN THERAPY, 2023, 40 (05) : 2355 - 2374
[29] Axicabtagene-ciloleucel/tocilizumabCytokine release syndrome and immune effector cell-associated neurotoxicity syndrome : case report
Reactions Weekly, 2022, 1921 (1) : 55 - 55
[30] Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States
Christopher Parker
Fei Fei Liu
Kristen A. Deger
Conrado Franco-Villalobos
Irina Proskorovsky
Scott J. Keating
Sonja Sorensen
Advances in Therapy, 2023, 40 : 2355 - 2374

← 1 2 3 4 5 →